Table 1.
Population baseline characteristics according to ART regimen.
| Patients remaining on 3DR | Patients changing to 2DR | p value | |
|---|---|---|---|
| N=90 | N=58 | ||
| Age (mean, [SD]) | 37 (9) | 40 (11) | 0.106 |
| Gender, n (%) | 0.936 | ||
| Male | 78 (87) | 50 (86) | |
| Female | 12 (13) | 9 (14) | |
| Mode of transmission, n(%) | 0.972 | ||
| MSM | 69 (67) | 38 (65) | |
| Heterosexual | 21 (23) | 15 (26) | |
| IDU | 6 (7) | 15 (26) | |
| Unknown | 3 (3) | 2 (3) | |
| Spanish Origin, n (%) | 59 (66) | 36 (62) | 0.666 |
| Education level, n (%) | 0.748 | ||
| No studies or compulsory | 13 (14.4) | 4 (17.4) | |
| Upper secondary or university | 64 (71.1) | 17 (73.9) | |
| Unknown | 13 (14.4) | 2 (8.7) | |
| AIDS diagnosis, n (%) | 14 (16) | 8 (14) | 0.769 |
| HCV positive ever, n (%) | 12 (13) | 6 (10) | 0.615 |
| Maximum HIV-1 RNA (c/mL), median (IQR) | 114500 (33770-344426) | 93599 (36307-219000) | 0.377 |
| < 100000, n (%) | 42 (46.7) | 32 (55.2) | 0.312 |
| ≥ 100000, n (%) | 48 (53.3) | 26 (44.8) | |
| Time from ART initiation to virologic suppression (years), median (IQR) | 0.5 (0.2-0.9) | 0.5 (0.3-0.9) | 0.126 |
| Virologic failure ever, n (%) | 6 (6.7%) | 1 (1.7%) | 0.167 |
| Low level viremia ever, n (%) | 4 (4.4%) | 0 (0%) | 0.104 |
| Time from virologic suppression (years) to ART switch, median (IQR) | – | 3.5 (1.9-5.2) | – |
| Nadir CD4 cell count (cells/μL), median (IQR) | 300 (151-373) | 259 (112-382) | 0.309 |
| Number of samples analyzed, median (min, max) | 4 (3-11) | 3 (3-8) | < 0.001 |
| Follow-up (years), median (IQR) | 3.9 (2.5-4.7) | 5.3 (3.9-6.8) | < 0.001 |
TT, triple therapy; 2DR, 2-drug combinations; ART, antiretroviral therapy; IDU, injecting drug use; MSM, men who have sex with men.